International review of neurobiology最新文献_第9页

Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence. 羟丁酸钠：对治疗酒精戒断综合征和酒精依赖症的疗效和安全性进行全面审查。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-20 DOI: 10.1016/bs.irn.2024.07.005

Julien Guiraud, Wim van den Brink

{"title":"Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence.","authors":"Julien Guiraud, Wim van den Brink","doi":"10.1016/bs.irn.2024.07.005","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.005","url":null,"abstract":"Alcohol dependence (AD) significantly impacts public health, affecting 3.4% of people aged 18-64 and contributing to around 12% of overall mortality. Individuals with AD have a markedly reduced life expectancy, dying up to 28 years earlier than the general population. Current treatments for AD show limited efficacy, with many patients not responding to these interventions, highlighting the need for new therapeutic options with novel mechanisms of action. Sodium oxybate (SMO), the sodium salt of GHB, is one such candidate, pharmacologically similar to alcohol; it acts on several neurotransmitters including GABA, potentially mitigating withdrawal symptoms and craving for alcohol. SMO has been clinically used in Italy and Austria since the 1990s, approved for treating alcohol withdrawal syndrome (AWS) and for maintaining abstinence in AD patients. Several randomized clinical trials (RCTs) and meta-analyses showed evidence of SMO to be effective and safe in these indications. For AWS, SMO was more effective than placebo and as effective as benzodiazepines in reducing withdrawal symptoms. For maintaining abstinence, SMO significantly improved continuous abstinence duration and abstinence rate compared to placebo. Comprehensive clinical data indicate that SMO is well-tolerated, with main adverse effects being mild, such as dizziness and vertigo, and serious adverse events being rare. The effectiveness and safety of SMO, coupled with its approval in two EU countries affirm its potential as a treatment option for AD, particularly in severe cases. Further RCTs, especially with stratification by severity of dependence, are suggested to refine our understanding of its efficacy across different patient subgroups.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"213-281"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy. 酒精依赖症患者的替代疗法：作用机制和疗效。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-16 DOI: 10.1016/bs.irn.2024.03.005

Julien Guiraud, Rainer Spanagel, Wim van den Brink

{"title":"Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy.","authors":"Julien Guiraud, Rainer Spanagel, Wim van den Brink","doi":"10.1016/bs.irn.2024.03.005","DOIUrl":"10.1016/bs.irn.2024.03.005","url":null,"abstract":"New approaches for the treatment of alcohol dependence (AD) may improve patient outcomes. Substitution maintenance therapy is one of the most effective treatment options for opioid and nicotine use disorders. So far, there has been little attention to substitution therapy for the treatment of AD. Here, we explain the mechanistic foundations of alcohol substitution maintenance therapy. Alcohol has many primary targets in the brain (and other organs) and the physical interaction of ethanol molecules with these specific ethanol-sensitive sites on a variety of ionotropic receptors (e.g. GABA-A, NMDA, and nicotinic acetylcholine (nACh) receptors) and ion channels provides the rationale for substitution. As such, a variety of compounds can interact with those ethanol-sensitive sites and can thus substitute for some of the effects of alcohol. For some of these compounds, alcohol discrimination studies have shown their substitution potential. Accordingly, potential substitution treatments include agonists acting at GABA receptors such as sodium oxybate, baclofen and benzodiazepines, NMDA receptor antagonists such as ketamine and memantine, or nAChRs agonists such as varenicline. All these compounds are already approved for other indications and we present clinical evidence for these drugs in the treatment of alcohol withdrawal syndrome (AWS) and in the long-term treatment of AD, and outline future steps for their acceptance as substitution treatment in AD. Finally, we discuss the substitution approach of managed alcohol programs for the most severely affected homeless populations. Results showed that sodium oxybate is probably the closest to a substitution therapy for AD and is already approved for the treatment of AWS and in the long-term treatment of AD in some countries. In conclusion, we argue that better AD treatment can be provided if substitution maintenance treatments for alcohol are implemented at a similar scale as for opioid and nicotine use disorder.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"175 ","pages":"187-239"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140330373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives. 减少酒精的危害：营养干预和功能性酒精替代品。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-03-19 DOI: 10.1016/bs.irn.2024.03.001

Delia Belelli, Antonio Riva, David John Nutt

引用次数: 0

Neuromodulation for neuropathic pain. 神经调控治疗神经病理性疼痛。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-11-16 DOI: 10.1016/bs.irn.2024.10.013

Pedro Henrique Martins da Cunha, Jorge Dornellys da Silva Lapa, Koichi Hosomi, Daniel Ciampi de Andrade

{"title":"Neuromodulation for neuropathic pain.","authors":"Pedro Henrique Martins da Cunha, Jorge Dornellys da Silva Lapa, Koichi Hosomi, Daniel Ciampi de Andrade","doi":"10.1016/bs.irn.2024.10.013","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.10.013","url":null,"abstract":"The treatment of neuropathic pain (NeP) often leads to partial or incomplete pain relief, with up to 40 % of patients being pharmaco-resistant. In this chapter the efficacy of neuromodulation techniques in treating NeP is reviewed. It presents a detailed evaluation of the mechanisms of action and evidence supporting the clinical use of the most common approaches like transcutaneous electrical nerve stimulation (TENS), transcranial direct current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS), invasive motor cortex stimulation (iMCS), spinal cord stimulation (SCS), dorsal root ganglion stimulation (DRG-S), and peripheral nerve stimulation (PNS). Current literature suggests that motor cortex rTMS is effective for peripheral and central NeP, and TENS for peripheral NeP. Evidence for tDCS is inconclusive. DBS is reserved for research settings due to heterogeneous results, while iMSC has shown efficacy in a small randomized trial in neuropathic pain due to stroke and brachial plexus avulsion. SCS has moderate evidence for painful diabetic neuropathy and failed back surgery syndrome, but trials were not controlled with sham. DRG-S and PNS have shown positive results for complex regional pain syndrome and post-surgical neuropathic pain, respectively. Adverse effects vary, with non-invasive techniques showing local discomfort, dizziness and headache, and DBS and SCS hardware-related issues. To date, non-invasive techniques have been more extensively studied and some are included in international guidelines, while the evidence level for invasive techniques are less robust, potentially suggesting their use in a case-by-case indication considering patient´s preferences, costs and expected benefits.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"179 ","pages":"471-502"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Placebo effects in neuropathic pain conditions. 神经性疼痛的安慰剂效应。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-29 DOI: 10.1016/bs.irn.2024.10.006

Simple Futarmal Kothari, Christina Emborg, Lene Vase

{"title":"Placebo effects in neuropathic pain conditions.","authors":"Simple Futarmal Kothari, Christina Emborg, Lene Vase","doi":"10.1016/bs.irn.2024.10.006","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.10.006","url":null,"abstract":"Management of neuropathic pain is exceptionally challenging and development of new drugs and ways to optimize treatment effects in clinical practice are needed. Over the last decade, some of the mechanisms underlying placebo effects have been elucidated and some of the insights have the potential to improve the treatment for neuropathic pain. Research suggests that the increasing placebo responses observed in randomized controlled trials (RCTs) for neuropathic pain pose challenges for the development and availability of new effective pain medications. In neuropathic pain, these placebo responses are typically not controlled for the natural history of pain and other confounding factors. Thus, our knowledge about the magnitude and mechanisms of placebo effects in neuropathic pain is sparse. A few mechanistic studies investigating placebo effects by controlling for natural history of pain have found large placebo analgesia effects in neuropathic pain. Psychological factors such as expectations and emotions play a substantial role in inducing the placebo effects. Here, we review placebo effects and the psychological and neurobiological mechanisms contributing to the placebo effects. The knowledge obtained from studies of placebo mechanisms can help improve the information that can be obtained from RCTs and potentially improve development of new pain medications and optimize treatment of neuropathic pain in clinical practice.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"179 ","pages":"155-179"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small fiber neuropathy. 小纤维神经病

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-29 DOI: 10.1016/bs.irn.2024.10.001

Dennis Kool, Janneke Gj Hoeijmakers, Stephen G Waxman, Catharina G Faber

{"title":"Small fiber neuropathy.","authors":"Dennis Kool, Janneke Gj Hoeijmakers, Stephen G Waxman, Catharina G Faber","doi":"10.1016/bs.irn.2024.10.001","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.10.001","url":null,"abstract":"Small fiber neuropathy (SFN) is a condition involving the small nerve fibers of the peripheral nervous system, specifically the thinly myelinated Aδ and unmyelinated C fibers. It is an increasingly acknowledged condition within the spectrum of neuropathic pain disorders, leading to a rise in diagnosed patients. SFN is characterized by neuropathic pain, that is often described as burning, and typically presents in the hands and feet ascending proximally. Since small nerve fibers are involved in the autonomic nervous system, SFN can also lead to autonomic dysfunction. In the clinical setting, SFN diagnosis is frequently based on the Besta Criteria, which include skin biopsy and quantitative sensory testing. For clinical trials, the ACTTION criteria are also recommended. However, the diagnostic process is often complex, prompting research towards more accessible diagnostic methods. The pathophysiology of SFN remains unclear, thereby challenging therapeutic strategies. A large variety of underlying conditions has been associated with SFN, including metabolic, immune-mediated, infectious, toxic and hereditary conditions. The discovery of genetic sodium channelopathies in SFN provides insight into its underlying mechanisms. Newly discovered mutations within these genes reveal that SFN often shows overlapping clinical presentations with other sodium channelopathies. This chapter provides an in-depth look at SFN, including its clinical features, diagnostic methods, underlying conditions and possible therapeutic strategies.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"179 ","pages":"181-231"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142696229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacology of neuropathic pain. 神经性疼痛的临床药理学。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-11-12 DOI: 10.1016/bs.irn.2024.10.012

Jan Rosner, Nadine Attal, Nanna B Finnerup

引用次数: 0

GABAergic compounds for the treatment of alcohol use disorder. 用于治疗酒精使用障碍的 GABA 能化合物。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-08-17 DOI: 10.1016/bs.irn.2024.08.001

Laís F Berro, James K Rowlett, Donna M Platt

{"title":"GABAergic compounds for the treatment of alcohol use disorder.","authors":"Laís F Berro, James K Rowlett, Donna M Platt","doi":"10.1016/bs.irn.2024.08.001","DOIUrl":"10.1016/bs.irn.2024.08.001","url":null,"abstract":"Decades of research have implicated the gamma-aminobutyric acid (GABA)ergic system as one of the main mediators of the behavioral effects of alcohol. Of importance, the addiction-related effects of alcohol also have been shown to be mediated in part by GABAergic systems, raising the possibility that pharmacotherapies targeting GABAergic receptors may be promising candidates for the treatment of alcohol use disorder (AUD). Alcohol modulates the activity of GABAA and GABAB receptors, and studies show that compounds targeting some of those receptors may decrease the addiction-related behavioral effects of alcohol. Specifically, drugs that share similar pharmacological properties with alcohol, such as positive allosteric modulators (PAMs) of GABAA and GABAB receptors, have been proposed as substitution therapies for AUD. Available evidence also suggests that negative allosteric modulators (NAMs) of GABAergic receptors may be potential therapeutics for AUD, although this effect is selective for specific receptor subtypes. Therefore, this Chapter reviews the available evidence on the use of GABAergic compounds for the treatment of AUD. Several GABAA and GABAB ligands show promising results, with a particularly positive therapeutic profile demonstrated for α5GABAA receptor NAMs, α4/6δGABAA receptor modulators (both positive and negative, including neurosteroids), and GABAB receptor PAMs. As newer and better GABAergic compounds become available, future research should focus on understanding how these ligands can modulate different clinical symptoms of AUD, with potential new areas of research encompassing alcohol withdrawal syndrome and AUD-related insomnia.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"383-399"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological activators of ALDH2: A new strategy for the treatment of alcohol use disorders. ALDH2 的药理激活剂：治疗酒精使用障碍的新策略。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-10-24 DOI: 10.1016/bs.irn.2024.07.003

Sofía Adasme-Reyes, Juan Fuentes, Ignacio Gutiérrez-Vega, Eduardo Isla, Vicente Pérez, Carolina Ponce, María Elena Quilaqueo, Mario Herrera-Marschitz, María Elena Quintanilla, David Vásquez, Mario Rivera-Meza

{"title":"Pharmacological activators of ALDH2: A new strategy for the treatment of alcohol use disorders.","authors":"Sofía Adasme-Reyes, Juan Fuentes, Ignacio Gutiérrez-Vega, Eduardo Isla, Vicente Pérez, Carolina Ponce, María Elena Quilaqueo, Mario Herrera-Marschitz, María Elena Quintanilla, David Vásquez, Mario Rivera-Meza","doi":"10.1016/bs.irn.2024.07.003","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.003","url":null,"abstract":"In mammals, ethanol is metabolized to acetaldehyde mainly by the liver alcohol dehydrogenase (ADH), and acetaldehyde is subsequently oxidized to acetate by mitochondrial aldehyde dehydrogenase (ALDH2). The presence of an inactive variant of ALDH2 or the use of inhibitors of this enzyme leads to an accumulation of acetaldehyde after ethanol consumption, generating an aversive reaction that inhibits subsequent alcohol intake. However, experimental evidence shows that acetaldehyde has potent rewarding effects at the central level, suggesting that acetaldehyde would be responsible for the addictive effect of alcohol. Alda-1 is an organic molecule that acts as a pharmacological activator of ALDH2. Studies in animal models of alcohol use disorders (AUD; i.e. alcoholism) have shown that Alda-1 can inhibit the acquisition, the chronic intake, and the relapse of alcohol consumption. These effects are reversible without any effects on water consumption or other natural reinforcer such as saccharin. It has also been reported that Alda-1 can act as a protective agent from the toxic effects on various tissues and organs mediated by ethanol-derived acetaldehyde, including liver damage, cancer, and central nervous system (CNS) alterations. Using in silico tools such as molecular docking the identification of important molecular interactions between Alda-1 and ALDH2 has been demonstrated, identifying new molecules with higher pharmacological features. Thus, there is now preclinical evidence supporting the use of activators of ALDH2 as a pharmacological strategy for the treatment of AUD.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"153-177"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ayahuasca for the treatment of alcohol use disorder. 治疗酗酒症的死藤水。

International review of neurobiology Pub Date : 2024-01-01 Epub Date: 2024-08-10 DOI: 10.1016/bs.irn.2024.07.007

Eduardo A V Marinho, Yasmim A Serra, Alexandre J Oliveira-Lima, Tânia Marcourakis, Laís F Berro

{"title":"Ayahuasca for the treatment of alcohol use disorder.","authors":"Eduardo A V Marinho, Yasmim A Serra, Alexandre J Oliveira-Lima, Tânia Marcourakis, Laís F Berro","doi":"10.1016/bs.irn.2024.07.007","DOIUrl":"https://doi.org/10.1016/bs.irn.2024.07.007","url":null,"abstract":"For decades, psychedelics have been investigated for the treatment of psychiatric disorders. Specifically, evidence suggests that psychedelics may have therapeutic potential for the treatment of alcohol use disorder. Several studies with classic psychedelics, including LSD and psilocybin, show promising results, with psychedelics decreasing alcohol drinking and promoting abstinence in individuals with alcohol use disorder. In the last two decades, ayahuasca has emerged as another psychedelic with therapeutic potential for alcohol use disorder. Although its use by indigenous people from South America has been reported for thousands of years, ayahuasca, an Amazonian brewed beverage used in rituals, has gained attention in recent decades due to its reported effects in the central nervous system. Ayahuasca is a hallucinogenic beverage produced from the decoction of Banisteriopsis caapi and Psychotria viridis, plants that contain β-carbolines and N,N-dimethyltryptamine (DMT), respectively. The majority of clinical studies investigating ayahuasca for the treatment of alcohol use disorder are retrospective, and all show a significant decrease in alcohol use among ayahuasca users. Corroborating the clinical evidence, pre-clinical studies also have demonstrated that ayahuasca can block several of the abuse-related effects of alcohol. This chapter reviews the accumulating evidence from clinical and pre-clinical studies suggesting that ayahuasca may be a promising new pharmacotherapy for the treatment of alcohol use disorders, and discusses the potential mechanisms involved in these and other effects of ayahuasca.","PeriodicalId":94058,"journal":{"name":"International review of neurobiology","volume":"178 ","pages":"283-300"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142635019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0